MidWestOne Financial Group Inc. Has $3 Million Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

MidWestOne Financial Group Inc. increased its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 10.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 24,347 shares of the specialty pharmaceutical company's stock after acquiring an additional 2,284 shares during the period. MidWestOne Financial Group Inc.'s holdings in Jazz Pharmaceuticals were worth $2,998,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. IFP Advisors Inc bought a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at $25,000. Quadrant Capital Group LLC increased its position in shares of Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock worth $25,000 after purchasing an additional 101 shares in the last quarter. Elequin Capital LP lifted its holdings in Jazz Pharmaceuticals by 677.8% during the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock valued at $26,000 after purchasing an additional 183 shares during the last quarter. CoreFirst Bank & Trust acquired a new position in Jazz Pharmaceuticals in the fourth quarter valued at about $28,000. Finally, Allianz SE bought a new stake in Jazz Pharmaceuticals during the fourth quarter worth about $29,000. Institutional investors own 89.14% of the company's stock.

Analyst Ratings Changes

JAZZ has been the subject of a number of research analyst reports. Robert W. Baird cut their target price on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Cantor Fitzgerald downgraded Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and lifted their price objective for the company from $140.00 to $150.00 in a research report on Wednesday, February 26th. UBS Group upgraded Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and increased their target price for the stock from $145.00 to $179.00 in a report on Friday, March 7th. Needham & Company LLC restated a "buy" rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Finally, Wells Fargo & Company upgraded shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and upped their price target for the stock from $130.00 to $170.00 in a research report on Thursday, February 13th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $182.79.

Jazz Pharmaceuticals Trading Up 0.2%

Jazz Pharmaceuticals stock traded up $0.25 during trading hours on Monday, reaching $108.07. 958,795 shares of the company's stock traded hands, compared to its average volume of 851,979. The firm has a market capitalization of $6.66 billion, a price-to-earnings ratio of 15.22, a PEG ratio of 1.04 and a beta of 0.38. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a fifty-two week low of $95.49 and a fifty-two week high of $148.06. The firm's 50 day moving average is $112.87 and its 200-day moving average is $121.97.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The business had revenue of $897.84 million during the quarter, compared to analyst estimates of $984.16 million. During the same quarter in the prior year, the company earned $2.68 earnings per share. The company's quarterly revenue was down .5% on a year-over-year basis. On average, analysts predict that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current year.

Insider Transactions at Jazz Pharmaceuticals

In related news, Director Seamus Mulligan bought 1,621 shares of the business's stock in a transaction on Monday, May 12th. The shares were purchased at an average price of $103.00 per share, with a total value of $166,963.00. Following the completion of the purchase, the director now owns 101,621 shares of the company's stock, valued at $10,466,963. This represents a 1.62% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Bruce C. Cozadd sold 6,500 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $144.25, for a total value of $937,625.00. Following the transaction, the chief executive officer now owns 464,058 shares of the company's stock, valued at $66,940,366.50. The trade was a 1.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 28,236 shares of company stock worth $3,956,190 in the last three months. Insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.